These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration.
    Author: Baker R.
    Journal: BETA; 1995 Dec; ():8. PubMed ID: 11363015.
    Abstract:
    The Food and Drug Administration (FDA) has approved oral ganciclovir (Cytovene) to prevent initial episodes of CMV retinitis and other forms of CMV disease among individuals with advanced AIDS (fewer than 100 CD4 cell/mm3). The recommended dosage for primary prophylaxis and maintenance treatment of CMV retinitis is 3,000 mg/day. This dosage would cost around fifty dollars. Cytovene may cause serious bone marrow suppression. Patient profiles should dictate appropriateness of Cytovene use.
    [Abstract] [Full Text] [Related] [New Search]